Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly Statement on FDA Advisory Committee Review of Necitumumab

[PR Newswire] – INDIANAPOLIS, July 9, 2015 /PRNewswire/ — The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met today to discuss the data supporting Eli Lilly and Company’s (NYSE: . . . → Read More: Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly Statement on FDA Advisory Committee Review of Necitumumab Similar Articles: Company Update (NYSE:LLY): Lilly Announces Webcast to Discuss Ixekizumab Phase III Data Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly Declares Second-Quarter 2015 Dividend Market Update (NYSE:LLY): Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement